Cargando…
TNFα inhibitor C87 sensitizes EGFRvIII transfected glioblastoma cells to gefitinib by a concurrent blockade of TNFα signaling
OBJECTIVE: More than half of human glioblastomas show EGFR gene amplification and mutation, but EGFR inhibitors have not been effective in treating EGFR-positive glioblastoma patients. The mechanism behind this type of primary resistance is not well understood. The aim of this study was to investiga...
Autores principales: | Ma, Li, She, Chunhua, Shi, Qian, Yin, Qiang, Ji, Xinxin, Wang, Yongrong, Fan, Yulong, Kong, Xinyao, Li, Peng, Sun, Zengfeng, Zhang, Xiaohui, Zhang, Zhen, Wang, Jian, Wang, Tong, Xu, Yuanfu, Li, Wenliang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Chinese Anti-Cancer Association
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6743627/ https://www.ncbi.nlm.nih.gov/pubmed/31565489 http://dx.doi.org/10.20892/j.issn.2095-3941.2019.0011 |
Ejemplares similares
-
Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII
por: Pedersen, M W, et al.
Publicado: (2005) -
EGFRvIII does not affect radiosensitivity with or without gefitinib treatment in glioblastoma cells
por: Struve, Nina, et al.
Publicado: (2015) -
Effects of Aptamer to U87-EGFRvIII Cells on the Proliferation, Radiosensitivity, and Radiotherapy of Glioblastoma Cells
por: Zhang, Xingmei, et al.
Publicado: (2018) -
Effects of Aptamer to U87-EGFRvIII Cells on the Proliferation, Radiosensitivity, and Radiotherapy of Glioblastoma Cells
por: Zhang, Xingmei, et al.
Publicado: (2023) -
EGFRvIII: the promiscuous mutation
por: Greenall, Sameer A, et al.
Publicado: (2016)